ANI PHARMACEUTICALS, INC Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $813.00K, a 47.55% increase year-over-year.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $19.75M, a 97.49% increase year-over-year.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $611.00K, a 92.14% increase year-over-year.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $1.04M, a 53.53% increase year-over-year.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for fiscal 2025 was $12.21M, a 11.41% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for fiscal 2024 was $10.96M, a 119.75% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for fiscal 2023 was $4.99M, a 154.57% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC treasury stock, value, acquired, cost method for fiscal 2022 was $1.96M, a 120.36% increase from fiscal 2021.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $813.00K 10-Q · filed 2026-08-07 | $22.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $19.75M 10-Q · filed 2026-05-08 | $21.96M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $611.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.21M 10-K · filed 2026-02-27 |
| 2025-09-30 | $1.04M 10-Q · filed 2025-11-07 | $11.92M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $551.00K 10-Q · filed 2026-08-07 | $11.55M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $10.00M 10-Q · filed 2026-05-08 | $12.30M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.96M 10-K · filed 2026-02-27 |
| 2024-09-30 | $680.00K 10-Q · filed 2025-11-07 | $10.87M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-08 | $10.86M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $8.66M 10-Q · filed 2025-05-09 | $10.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.99M 10-K · filed 2026-02-27 |
| 2023-09-30 | $670.00K 10-Q · filed 2024-11-08 | $4.88M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $537.00K 10-Q · filed 2024-08-06 | $4.44M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $3.55M 10-Q · filed 2024-05-10 | $4.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.96M 10-K · filed 2025-02-28 |
| 2022-09-30 | $239.00K 10-Q · filed 2023-11-08 | $1.84M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $483.00K 10-Q · filed 2023-08-09 | $1.67M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.12M 10-Q · filed 2023-05-08 | $1.66M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $889.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $73.00K 10-Q · filed 2022-11-09 | $889.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $468.00K 10-Q · filed 2022-08-08 | $816.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $348.00K 10-Q · filed 2022-05-10 | $1.38M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.52M 10-K · filed 2023-03-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $1.52M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $1.03M 10-Q · filed 2021-08-06 | $1.52M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $488.00K 10-Q · filed 2021-05-07 | $1.21M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.03M 10-K · filed 2022-03-15 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.03M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $723.00K 10-Q · filed 2020-08-06 | $1.03M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $308.00K 10-Q · filed 2020-05-07 | $717.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $659.00K 10-K · filed 2021-03-11 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | |
| 2018-06-30 | $409.00K 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $250.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $259.00K 10-K · filed 2020-02-27 | |
| 2016-12-31 | $122.00K 10-K · filed 2019-02-27 | |
| 2015-12-31 | $113.00K 10-K · filed 2018-02-27 | |
| 2013-12-31 | $433.00K 10-K · filed 2016-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |